- Home
- FIGX vs ACIU Comparison
FIGX vs ACIU Comparison
Compare FIGX & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIGX
- ACIU
- Stock Information
- Founded
- FIGX 2025
- ACIU 2003
- Country
- FIGX United States
- ACIU Switzerland
- Employees
- FIGX N/A
- ACIU N/A
- Industry
- FIGX
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- FIGX
- ACIU Health Care
- Exchange
- FIGX Nasdaq
- ACIU Nasdaq
- Market Cap
- FIGX 193.9M
- ACIU 213.3M
- IPO Year
- FIGX 2025
- ACIU 2016
- Fundamental
- Price
- FIGX $10.01
- ACIU $3.75
- Analyst Decision
- FIGX
- ACIU Strong Buy
- Analyst Count
- FIGX 0
- ACIU 2
- Target Price
- FIGX N/A
- ACIU $10.00
- AVG Volume (30 Days)
- FIGX 16.2K
- ACIU 461.9K
- Earning Date
- FIGX 01-01-0001
- ACIU 10-31-2025
- Dividend Yield
- FIGX N/A
- ACIU N/A
- EPS Growth
- FIGX N/A
- ACIU N/A
- EPS
- FIGX N/A
- ACIU N/A
- Revenue
- FIGX N/A
- ACIU $36,362,036.00
- Revenue This Year
- FIGX N/A
- ACIU N/A
- Revenue Next Year
- FIGX N/A
- ACIU $1,022.98
- P/E Ratio
- FIGX N/A
- ACIU N/A
- Revenue Growth
- FIGX N/A
- ACIU 86.71
- 52 Week Low
- FIGX $9.95
- ACIU $1.43
- 52 Week High
- FIGX $10.06
- ACIU $4.00
- Technical
- Relative Strength Index (RSI)
- FIGX N/A
- ACIU 65.46
- Support Level
- FIGX N/A
- ACIU $3.23
- Resistance Level
- FIGX N/A
- ACIU $4.00
- Average True Range (ATR)
- FIGX 0.00
- ACIU 0.32
- MACD
- FIGX 0.00
- ACIU 0.05
- Stochastic Oscillator
- FIGX 0.00
- ACIU 85.28
About FIGX FIGX Capital Acquisition Corp. Class A Ordinary Share
FIGX Capital Acquisition Corp is a blank check company.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.